Pharma & Biotech Global Week in Review 16 May 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Losec (Omeprazole) – EU: AstraZeneca fine for misleading patent regulators looks fine, says AG Mazák: AstraZeneca v European Commission (IPKat)

Australia: High Court refuses application for special leave to appeal Full Court finding that extended release venlafaxine patent is invalid (IP Whiteboard)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

DNDi backs WHO ‘neglected patients’ R&D treaty (IP Watch)

Key WIPO committee on patents to discuss patents and health, exceptions and limitations to patent rights and opposition systems (KEI)

New IFPMA-backed report on R&D for diseases in developing countries (IP Watch)

Australia: Gene patent opponents take the fight back to Australian Parliament (Patentology)

Argentina: New guidelines for the examination of pharmaceutical patents in Argentina (IP tango) (IP tango)

India: Parliamentary Standing Committee on Health tables damning report on the dangerous liaisons between the DCGI & the pharmaceutical industry (Spicy IP)

UK: EWCA applied CJEU’s ruling concerning Medeva’s applications for SPCs relating to combination vaccines: Medeva v Comptroller General of Patents (EPLAW)

US: James Love’s testimony for Senate HELP hearing on S.1138, the Prize Fund for HIV/AIDS (KEI)

US: Statement of Sen. Bernard Sanders (I-VT) on the mark-up of FDA reauthorization package (KEI)

US: New reports on FDA drug approval performance emerge as House Committee considers user fee reauthorization legislation (FDA Law Blog)

US: USPTO seeks comments on new sequence listing standard (Patent Docs)

US: Decisions, decisions, decisions! Our updated labeling carve-out citizen petition scorecard (FDA Law Blog)

US: Esoterix Genetic Laboratories files patent infringement suit against Life Technologies over products used in detecting certain cells or changes in a biological sample (Patent Docs)

US: Precision BioSciences asserts patent entitled “Methods of cleaving DNA with rationally-designed meganucleases’ against Cellectis in ED North Carolina (Patent Docs)

 

Products

Altace (Ramipril) – US: CAFC split on inherency in In re Montgomery (IPBiz) (Patent Docs)

Amrix (Cyclobenzaprine) – US: CAFC reverses finding of obviousness: In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation (Patent Docs)

Boniva (Ibandronic acid) – US: District Court New Jersey deems Boniva patent obvious on summary judgment: Hoffman-La Roche v Apotex (Docket Report)

Botox (Botulinum) – EU: CJEU refuses bids by L’Oreal and Helena Rubinstein to register Botox-like trade marks (IPKat)

Cosopt (Dorzolamide, Timolol) – Netherlands: Court of Appeal of The Hague affirms lower court decision that patent and corresponding SPC are invalid for lack of inventive step: MSD v Sandoz and Hexal (EPLAW)

Coversyl (Perindopril) – UK: EWCA: Pharmaceutical firm wins battle for compensation following the lifting of injunction: Les Laboratoires Servier v Apotex (Out-Law)

Effexor (Venlafaxine) – Australia: High Court refuses application for special leave to appeal Full Court finding that  extended release venlafaxine patent is invalid (IP Whiteboard)

Losec (Omeprazole) – EU: AstraZeneca fine for misleading patent regulators looks fine, says AG Mazák: AstraZeneca v European Commission (IPKat)

Nexavar (Sorafenib) – India’s first compulsory licence over Bayer’s patent: Natco v Bayer (JIPLP)

Precedex (Dexmedetomidine) – US: Inventor’s supervisory capacity and signature on report containing withheld data did not establish intent to deceive: Hospira v Sandoz (Docket Report)

Staxyn (Vardenafil) – US: Bayer Pharma files patent infringement suit against Watson in response to Para IV challenge (Patent Docs)

Tarceva (Erlotinib) – US: OSI files patent infringement suit against Roxane following Para IV certification (Patent Docs)

Xopenex (Levosalbutamol) – US: CAFC upholds declaratory judgment jurisdiction over subsequent ANDA litigation: Dey Pharma v Sunovion (Pharma Patents)

Zemplar (Paricalcitol) – US: Abbott files patent infringement suit against Agila Specialities in response to Para IV challenge (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,521 other followers

%d bloggers like this: